According to MattsonJack's Supportive CarePerspectives(TM) report series, cancer-induced nausea and vomiting(CINV), anemia, and neutropenia historically have been the high-profilesupportive care indications. However, the CINV market has becomeincreasingly competitive due to generic erosion as well as increasedefficacy benchmarks set by new branded agents such as Aloxi and the NK1receptor antagonists, driving development activities to focus onreformulations of existing products. The anemia market has been hit withtighter regulations for using erythropoietin-stimulating agents, causingcompanies to second-guess entering the cancer-related anemia market. Todate, the neutropenia and anemia markets in the United States and Japanhave been protected by manufacturing patents, although the adoption of aregulatory pathway for follow-on biologics as adopted in Europe couldincrease development in the future. However, the approval of follow-onbiologics in Europe has not spurred the development of innovative noveltherapies for anemia or neutropenia, only "me-too" products.

"Cachexia is one indication that has benefitted from companies focusingefforts away from these other indications," said Gordon Gochenauer, ProductManager for Supportive Care Perspectives(TM). "Anorexia / cachexia couldbecome one of the most competitive supportive care markets, with a largeadvantage going to the first novel agent approved for this indication."

Cancer-related cachexia affects approximately one-third of all cancerpatients, or about 1 million people in the U.S., 1.3 million in the fivemajor EU countries, and 300,000 in Japan. Treatment generally involvesagents that are off-patent. However, seven agents are in Phase II or PhaseIII development, with another two in Phase I; these nine agents representsix unique mechanisms of action.

More in-depth information on cachexia and 14 additional supportive careconditions is available in Supportive Care Perspectives(TM), the onlyresource providing in-depth analysis of supportive care in the U.S.oncology market as well as epidemiology for Western Europe and Japan.Unique features include:

-- Validation of epidemiology data and market opportunities, with patient populations available for the United States, Western Europe, and Japan-- Up-to-date analysis on the newest and most relevant agents in development-- In-depth primary market research with 2,479 physicians who treat 199,000 patients monthly

Supportive Care Perspectives(TM) contains detailed modules for the UnitedStates, including background, patient populations, current treatmentpractices, emerging products, and commercial perspectives, for thefollowing conditions:

-- Anemia-- Neutropenia-- Thrombocytopenia-- Mucositis-- Nausea and vomiting-- Anorexia / cachexia-- DVT / thrombosis-- Hypercalcemia-- Bone metastases-- Brain metastases

In addition, Supportive Care Perspectives(TM) provides briefings on diseasebackground, patient populations, therapy management, and emerging productson the following five conditions:

-- Xerostomia-- Neuropathy-- Pain-- Live metastases-- Lung metastases

For more information, contact Paula Paradise, Director of Marketing,MattsonJack Public Relations, at paula.paradise@mattsonjack.com or by phonein the U.S. (484.442.1431).

ABOUT THE MATTSON JACK GROUP, INC. (www.mattsonjack.com)

Formed in 1986, MattsonJack focuses its client support in three areas ofCompetency: Business Analytics, Brand Optimization, and CorporateDevelopment services in the pharmaceutical and biotech markets. MattsonJackconsultants have expertise in pricing and reimbursement, customepidemiology, technology assessment, business and strategic plandevelopment, due diligence and licensing support, market modeling andforecasting, and primary market research. MattsonJack's client list rangesfrom emerging companies to some of the most recognized pharmaceutical andbiotech companies in the world, such as Abbott, Amgen, AstraZeneca,Genentech, GlaxoSmithKline, Johnson & Johnson Companies, Merck, Novartis,Pfizer, Roche, Wyeth, and many others.

MattsonJack's knowledgeware and client productivity tools include EpiDatabase®, Forecast Architect®, and KeyMD®. Additionally,MattsonJack, as one of the largest global oncology consulting firms,supports its clients' cancer interests through its MattsonJack DaVincimulticlient offerings, including CancerMPact®, CancerNSight®, andOncologyMarketing Strategies(TM).

MattsonJack is part of Kantar Group, the information, insight, andconsultancy division of WPP, a world leader in marketing communicationsservices.

ABOUT KANTAR GROUP (www.kantargroup.com)

Kantar is one of the world's largest research, insight and consultancynetworks. It helps clients make better business decisions through a deeperunderstanding of their markets, their brands and their customers. Part ofWPP, Kantar brings together a diverse group of outstanding marketinginsight and consulting companies -- each an expert in their field who canwork together seamlessly to help clients address business issues in aholistic and strategic way.

Companies include: Added Value Group, IMRB, BMRB, BPRI, CannondaleAssociates, Center Partners, Everystone, Focalyst, Fusion 5, GlendinningManagement Consultants, Henley Centre HeadlightVision, IMRB, KantarOperations, KMR Group, Lightspeed Research, Management Ventures, TheMattson Jack Group, Inc., Millward Brown, Research International, RMS andZiment Group. The group operates in more than 160 offices across 60 marketsworldwide.

Add to Digg Bookmark with del.icio.us Add to Newsvine

CONTACT:Paula ParadiseDirector of MarketingMattsonJack Public RelationsEmail Contact484.442.1431